Glioblastoma Multiforme In The Pineal Region: Systematic Review Of The Survival Outcomes

DOI: https://doi.org/10.21203/rs.3.rs-898578/v1

Abstract

Purpose: Glioblastoma multiforme of the pineal region harbors high mortality in the first year of treatment. This study aims to deepen the study of pineal GBM patients for finding independent predictors of mortality, focusing on the therapeutic modalities and genetic features.

Methods: We present a systematic review of the long-term outcomes of the disease with a focus on the therapeutic modalities and genetic features.

Results: The median overall survival of the disease is 12 months. Biopsy (HR:4.2, p=0.002, and a median survival of 19 months) and radiochemotherapy (HR:4.1, p<0.001, and a median survival of 18 months) represent independent predictors of pineal glioblastoma survival. H3K27M mutant patients had a median survival of 23 months versus the ten-months median survival of the H3K27 wild type. However, no statistical difference exists due to the limited number of cases. The disease's local progression and recurrence seem higher in patients undergoing surgical removal than biopsy procedures (p=0.021).

Conclusions: Biopsy and radiochemotherapy represent independent predictors of pineal GBM survival. Surgical resection different from biopsy seems to increase the risks of local progression and recurrence. However, further studies should focus on the impact of the genetic profile on long-term outcomes.

Introduction

Pineal region glioblastoma multiforme (GBM) represents a very aggressive disease with high mortality in the first year after initial treatment. Previous reports with a few cases have suggested gross total resection (GTR) as an independent predictor of mortality, and biopsy and radiochemotherapy delivery represent independent predictors of pineal GBM patient survival [1, 2]. However, previous studies did not evaluate the pineal GBM genetic profile due to the limited report of cases [1]. Thus, the analysis of genetic mutations in GBM patients remains essential to draw adequate conclusions regarding the benefits and disadvantages of the therapeutic modalities.

This study aims to deepen the study of pineal GBM patients to define the independent predictors of mortality, focusing on the therapeutic modalities and genetic features.

Methods

Population study and design

We present a systematic review of all reported pineal GBM patients focused on the survival outcomes after different treatments. The systematic review followed PRISMA guidelines. Besides, we introduce two GBM patients operated on in Helsinki University Hospital, one of them as an illustrative case.

Data management

We conducted a systematic review of all pineal GBM patients published in the literature. The literature search was conducted using PubMed and SCOPUS databases on March 20, 2021, and actualized in June 2021 (Figure 1). Keywords in the search were: “((tectal) OR pineal) AND glioblastoma”. All available languages were included in the review. The inclusion criteria required histological confirmation. Two independent authors performed a comprehensive search of the literature and the data extraction for the study. Discrepancies were solved by consensus. The limited number of cases allowed an individual data analysis of all reported patients; however, it avoided performing the meta-analysis. Quality assessment tools were planned.

Statistical methods

We performed a descriptive analysis of the study population. Fisher exact test and T-test were appropriately used. Besides the individual data analysis, we compared the survival outcomes in terms of the presence of hydrocephalus, the regional dissemination of the disease, the size of the tumor, the extent of surgical resection, adjuvant radiotherapy, and chemotherapy. For this, a univariate and multivariate Cox regression model for survival analysis was performed. Log Rank test helped to determine the median overall survival (MOS) of the patients. IBM ® SPSS ® Statistics Version 27 was used for the statistical analysis. Only available data were analyzed, and missing data were not extrapolated. P-value was set at 0.05 for significance.

Results

Illustrative case

A 64-year-old female presented with headaches, progressive short-term memory deficits, and some degree of unbalance without other physical dysfunction. Figure 2 illustrates the pre and postoperative imaging. Brain MRI revealed a single highly contrast-enhanced 2x2x2cm lesion in the pineal region lying over the tectal plate associated with some degree of ventricular enlargement but minimal periventricular lucency. Serum hormonal tests for the pineal tumor diagnosis became negative, and the patient was prepared for direct microsurgical resection.

The patient underwent a right paramedian supracerebellar infratentorial approach in a sitting position with complete tumor removal and opening of the posterior third ventricle. During the immediate postoperative course, the patient did not develop new deficits. The histologic diagnosis was a World Health Organization (WHO) grade IV GBM. The patient received two cycles of temozolomide 150 mg/m2 and fractionated radiation therapy of 36 Gy distributed in daily doses of 3 Gy. However, she developed a Pneumocystis infection and Eaton-Lambert syndrome. Thus, radiochemotherapy was discontinued. The patient´s last evaluation was performed 10 months after surgery. MRI studies did not show any recurrence in the pineal region. However, multiple tumor foci with significant perilesional edema in the right cerebellar parenchyma and the right incisural space resulted in obstructive hydrocephalus. The patient died ten months after surgery due to disease progression.

Systematic review

Bibliography details

Patients were retrieved from 43 studies published between 1977 and 2021 (see data in brief-repository data) [1–43]. Moreover, three patients were retrieved from references of one published study [1] after full-text evaluation and diagnosis confirmation [44–46]. Other three patients were retrieved from other sources after diagnosis confirmation [47–49]. Individual participant data was collected to organize the study characteristics table. The original language of publications included English for all of them.

Patient related variables

We report 72 pineal region GBM patients (42% female) with an average age of 39 ± 19.2 (1 – 74) years. A summary of the findings is provided in Tables 1, 2, and 3. The clinical presentation of the patients did not differ from other pineal region lesions. However, 86% of the pineal GBM patients harbored hydrocephalus.

Disease characteristics

Among the 72 pineal GBM cases, four were reported as WHO grade IV Gliosarcomas [4, 38, 46]. At initial presentation, 22 (31%) patients did not have tumor imaging reports. 11/50 patients (22%)  had intracranial dissemination [1, 3, 11, 12, 22, 24, 43], and only one case reported spinal dissemination [43]. The few cases with CT scan reports did not describe calcifications. MRI studies mostly reported an unspecific lesion with a mean diameter of 29 ± 11 (6-50) mm, irregular borders, and heterogeneous enhancement without cystic components. Tumors with and without hydrocephalus had average diameters of 33.4mm and 26mm, respectively. No statistical difference was found due to the reduced number of cases with reported dimensions. Hydrocephalus management included direct removal of the tumor (10.6%), endoscopic third ventriculostomy (38.3%), and ventriculoperitoneal shunt (51.1%).

Immunogenetics

Immunogenetic reports were very limited to draw appropriate conclusions since only 30 (42%) patients detailed genetic profile information (Table 4) [1, 2, 6, 11–13, 15, 22, 24, 26, 29, 32, 35, 37, 38, 43, 46, 47]. Among 30 patients, H3K27 gene mutation was studied in 15 patients. IDH1 mutation in 15 patients, and Ki67 in 18 patients. Other common glioma genes mutations such as the PTEN mutation, ATRX lost, 1p/19q co-deletion, MGMTp methylation, EGFRvIII mutation underwent evaluation in 10 or a smaller number of patients. The few cases prevented to find of correlations between the genetic profile and disease progression. The survival analysis of the patients with the genetic profile is described in the section “predictors of overall survival”.

We did not find any association under the univariate and multivariate analysis as well. Thus, the H3K27M mutation did not correlate with any clinical or surgical variable. However, none of the seven H3K27M mutant patients followed GTR while 4/8 (50%) H3K27 wild type followed GTR (Fisher test p:0.077).

Surgical intervention and complementary therapy

Biopsy in 33% of this series, usually associated with radiochemotherapy, represented the most frequent treatment modality. Only 19% of the patients underwent gross total resection. Moreover, 89% and 76% of the patients underwent radiotherapy and chemotherapy, respectively. 75% of the patients underwent both radiochemotherapy and radiotherapy. Radiotherapy protocols included in most cases external boost radiotherapy of 60Gy distributed in daily doses of 2Gy. Chemotherapy protocols included Temozolomide in different schemes. Moreover, vincristine, cisplatin, optune, nivolumab, dichloroacetate, KPT-330, Avastin, bevacizumab, nimustine, valproic acid, thioguanine, lomustine, dibromodulcitol, ifosfamide, and etoposide were also reported.

Follow up and outcome

Table 1 summarizes the survival and radiological outcomes. The average follow-up (FU) of pineal region GBM patients was 12 ± 10 (0 – 42) months. 30% of the patients were alive at the last FU. The MOS of this series was 12 months. Information regarding the functional status of the patients at the last clinical evaluation was limited. At the last MRI evaluation of the patients, 23 (32%) patients did not report postoperative imaging. 13/49 (27%) patients did not present disease progression, and four of them were tumor-free. Among the rest of patients, 24/49 (49%) had local progression, 12/49 (25%) had intracranial metastasis, although 6/11 (55%) patients with intracranial metastasis at initial presentation did not report postoperative imaging. 7/49 (14%) patients presented spinal metastasis. All seven spinal metastases presented without pineal tumor progression but with intracranial metastasis in five cases. Similarly, 10/12 (83%) patients with regional intracranial metastasis presented without the primary pineal tumor progression. Thus, 12/14 (86%) patients with regional or spinal metastasis at the last FU did not associate primary pineal tumor progression. 4/49 (8.2%) patients had postoperative complications characterized by postoperative hemorrhage and infarctions.

Table 2 compares the differences among the primary surgical management of the patients. Metastatic disease at initial presentation did not have any association with the type of surgical treatment (Biopsy versus surgical removal) (Fisher exact test, p = 0.7). Regional and spinal metastases at the last MRI evaluation was similar among the different surgical treatment. However, patients undergoing biopsy and complementary therapy had reduced local progression of the disease compared to those following a more invasive surgical removal of the tumor (Fisher exact test, p = 0.021). Under univariate analysis, no other variables had a significant association with the progression of the disease at the last evaluation. The mortality of patients following biopsy was significantly inferior compared with patients undergoing surgical removal. The MOS of patients following biopsy was 19 months, while the MOS of patients following surgical removal was 12 months (Long Rank test, p = 0.018). Table 3 details the radiochemotherapy delivery. The mortality of patients following radiochemotherapy was significantly inferior compared with patients undergoing surgery alone. The MOS of patients following radiochemotherapy was 18 months, while the MOS of patients following surgery alone was six months (Long Rank test, p = 0.002). Moreover, the mortality of patients following biopsy plus radiochemotherapy (MOS of 19 months) was significantly inferior to patients following surgical removal without radiochemotherapy (MOS of 10 months) (Long Rank test, p = 0.010).

Predictors of overall survival

After univariate Cox survival analysis, predictors of better overall survival included biopsy procedures, radiotherapy, chemotherapy, and the association of radiotherapy plus chemotherapy (Table 5, Figure 3). After Cox survival multivariate regression analysis, independent variables associated with better survival rates included biopsy procedures and the association of radiotherapy plus chemotherapy (Table 5, Figure 4). It is worth noting that after multivariate regression analysis, radiotherapy (OR: 2.47, 95% CI: 0.78 – 7.86, p: 0.13) and chemotherapy (OR: 2.87, 95% CI: 0.75 – 10.97, p: 0.12) separately did not show independent association with better survival of the patients.

Due to the limited number of cases, we did not find differences in the Cox survival model evaluation among the 30 patients with different genetic profiles. Thus, the MOS of patients with H3K27M mutant was 23 months, and the MOS of patients with H3K27 wild type was ten months (Long Rank test, p = 0.3). However, it is worth noting that 5/7 (71%) patients with H3K27M mutant kept alive along 12±6 (7-23) months compared with the 88% (7/8) mortality of the H3K27 wild type patients after 13±7 (2-24) months (Fisher p = 0.041). Regarding other genetic markers, the distribution of the genetic profile did not significantly affect the overall survival of the patients.  

Pediatric population

Table 1 details the characteristic of the study population classified as patients younger and older than 20 years old. High male frequency in the adult population contrasted with the high female frequency in the pediatric population. However, the differences were not statistically significant (p = 0.063). Regarding treatment modalities, while adult patients followed surgical removal in most cases, pediatric patients followed biopsy (p = 0.023). Differences were insignificant regarding the sex, hydrocephalus, tumor dimensions, intracranial or spinal dissemination at initial presentation, the extent of surgical resection, radiotherapy delivery, chemotherapy delivery, postoperative complications, disease progression at the last MRI evaluation, clinical FU, nor survival rate.

Discussion

Pineal region GBM are uncommon lesions. Here, we present a systematic review of 72 pineal region GBM, the most comprehensive series reported in the literature. An evaluation of 47 pineal GBM performed by Niu et al. in 2020 represents the only available structured evaluation of this aggressive disease [1]. Our main findings are summarized as follow:

The findings of this systematic review include some similar conclusions to the previous publication. The average age of presentation was 39 years, unlike other common midline gliomas, such as thalamus or brainstem gliomas present in children [50–52]. However, pineal GBM does not have gender preference in this review differently from the previous report [1]. The clinical presentation of the disease was similar as previously reported. Most pineal GBM appear associated with Hydrocephalus. Imaging studies also showed different features without a standard pattern.

After univariate and multivariate analysis, biopsy and radiochemotherapy became independent predictors of pineal GBM survival. This finding correlates with previous reviews [1, 2]. The literature supports maximal GBM resection in cerebral hemisphere diffuse gliomas [53–56]. However, complete resection in pineal GBM was previously questioned [1, 2, 21, 57, 58]. This research supports biopsy and RT-CMT delivery as the most suitable approach for pineal region GBM. However, as discussed later in this section, the independent GBM survival prediction of biopsy and RT-CMT delivery may mask the genetic differences of the patients.

On the other hand, the risk of collateral damage and leptomeningeal dissemination produced by the radical pineal GBM removal -as showed in the illustrative case of this report-, may play a role in patient survival [1, 57, 58]. Postoperative regional and spinal metastasis are uncommon in most diffuse midline gliomas, such as thalamus or brainstem gliomas [50–52]. However, pineal GBM presents distal leptomeningeal intracranial and spinal dissemination. The multivariate analysis of our series did not demonstrate differences in the survival of those patients with leptomeningeal dissemination. Finally, the type of radiochemotherapy delivery would also affect the survival outcomes. Thus, further research is still required to validate the findings of this study.

According to the WHO Classification of Central Nervous System tumors published in 2016 [51], the classification of glial cell-derived tumors has changed based on the genotype-based diagnosis. Diffuse and non-diffuse gliomas characterize the two major groups of this classification. Multiple genetic markers to complement glioma diagnosis include the following: the isocitrate dehydrogenase (IDH1/IDH2) mutation, 1p/19q codeletion, histone H3 K27M mutation, RELA fusion, ATRX mutation, TP53 mutations, TERT promoter mutation, BRAF V600E mutation, and KIAA1549-BRAF fusion [59, 60]. In the 2016-WHO review, H3K27M mutation commonly belongs to the midline location tumors [51]. Previous studies reported different outcomes after comparing H3K27M mutant and wild types [50, 52, 56]. However, the limited number of pineal region GBM remains a limitation to discover the genetic background of these tumors [1].

The available comprehensive study on pineal GBM could not draw significant conclusions regarding the genetic features of the patients [1]. The few patients with genetic studies remain a limitation for obtaining appropriate inferences. Subsequently, although we could not find differences in the Cox survival analysis of genetic features regarding the H3K27 mutation, the rate of survivors at the same FU period was superior in the H3K27M mutant group compared to the H3K27 wild type patients. Moreover, none of the H3K27 mutation patients underwent GTR, compared to the 50% of H3K27 wild-type patients that underwent GTR. This finding suggests that independent prediction of survival by biopsy and RT-CMT delivery may mask the genetic differences of the GBM patients. Thus, the tumor aggressiveness reflected in the prompt recurrence and the regional and spinal dissemination may represent just the phenotypic expression of the genetic mutations. H3K27 and IDH mutations were the most common genetic aberrations in the few reports. The literature lacks information on other common glioma-gene mutations such as the PTEN mutation, ATRX lost, 1p/19q co-deletion, MGMTp methylation, EGFRvIII mutation, among others. Thus, further studies with proper genetic evaluation in pineal GBM patients remain essential to determine the real impact of the surgical approach and RT-CMT delivery in the patients´ survival.

The main limitation of this study represents the retrospective data collection from case reports or small series of patients. Moreover, we have tried to avoid losing patient data. Thus, all available data underwent analysis without extrapolating missing data. The conclusions of this study require further evaluation.

Declarations

GBM of the pineal region is a very aggressive disease with high mortality in the first year after initial treatment. Biopsy and radiochemotherapy represent independent predictors of pineal GBM survival. However, further studies should evaluate the impact of the genetic profile on long-term outcomes. Surgical resection different from biopsy seems to increase the risks of local progression and recurrence.

References

  1. Niu X, Wang C, Zhou X, et al (2021) Pineal Region Glioblastomas: Clinical Characteristics, Treatment, and Survival Outcome. World Neurosurgery 146:e799–e810. https://doi.org/10.1016/j.wneu.2020.11.016
  2. Stowe HB, Miller CR, Wu J, et al (2017) Pineal Region Glioblastoma, a Case Report and Literature Review. Frontiers in oncology 7:123. https://doi.org/10.3389/fonc.2017.00123 [doi]
  3. Amini A, Schmidt RH, Salzman KL, et al (2006) Glioblastoma multiforme of the pineal region. J Neurooncol 79:307–314. https://doi.org/10.1007/s11060-006-9145-x
  4. Banczerowski P, Vajda J, Bálint K, Sipos L (2012) Gliosarcoma of the pineal region with cerebellar metastasis: Case illustration. Ideggyogyaszati Szemle 65:40–41
  5. Behari S, Jaiswal S, Nair P, et al (2011) Tumors of the posterior third ventricular region in pediatric patients: The Indian perspective and a review of literature. Journal of pediatric neurosciences 6:S56-71. https://doi.org/10.4103/1817-1745.85713 [doi]
  6. Birbilis TA, Matis GK, Eleftheriadis SG, et al (2010) Spinal metastasis of glioblastoma multiforme: An uncommon suspect? Spine 35:E264–E269. https://doi.org/10.1097/BRS.0b013e3181c11748
  7. Bodhey NK, Purkayastha S, Gupta AK, Radhakrishnan VV (2006) Glioblastoma multiforme in the pineal region. A case report. Rivista di Neuroradiologia 19:229–231. https://doi.org/10.1177/197140090601900214
  8. Bonney PA, Boettcher LB, Cheema AA, et al (2015) Operative results of keyhole supracerebellar-infratentorial approach to the pineal region. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 22:1105–1110. https://doi.org/10.1016/j.jocn.2014.12.029 [doi]
  9. Chang CG, Kageyama N, Kobayashi T, et al (1981) Pineal Tumors: clinical diagnosis, with special emphasis on the significance of pineal calcification. Neurosurgery 8:656–668. https://doi.org/10.1227/00006123-198106000-00004 [doi]
  10. Cho BK, Wang KC, Nam DH, et al (1998) Pineal tumors: experience with 48 cases over 10 years. Child’s nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 14:53–58
  11. D’Amico RS, Zanazzi G, Wu P, et al (2018) Pineal region glioblastomas display features of diffuse midline and non-midline gliomas. Journal of neuro-oncology 140:63–73. https://doi.org/10.1007/s11060-018-2931-4
  12. Demir MK, Yaplcler O, Ozturk OC, Aslan M (2018) Posterior Third Ventricular Glioblastoma with Primary Leptomeningeal Metastasis in a Child. Pediatric neurosurgery 53:205–208. https://doi.org/10.1159/000485922
  13. Dono A, Takayasu T, Ballester LY, Esquenazi Y (2020) Adult diffuse midline gliomas: Clinical, radiological, and genetic characteristics. Journal of Clinical Neuroscience 82:1–8. https://doi.org/10.1016/j.jocn.2020.10.005
  14. Gasparetto EL, Warszawiak D, Adam GP, et al (2003) Glioblastoma multiforme of the pineal region: Case report. Arquivos de Neuro-Psiquiatria 61:468–472. https://doi.org/10.1590/s0004-282x2003000300027
  15. Gilbert AR, Zaky W, Gokden M, et al (2018) Extending the Neuroanatomic Territory of Diffuse Midline Glioma, K27M Mutant: Pineal Region Origin. Pediatr Neurosurg 53:59–63. https://doi.org/10.1159/000481513
  16. Gu Y, Zhou Q, Zhu W, et al (2019) The Purely Endoscopic Supracerebellar Infratentorial Approach for Resecting Pineal Region Tumors with Preservation of Cerebellomesencephalic Vein: Technical Note and Preliminary Clinical Outcomes. World Neurosurgery 128:e334–e339. https://doi.org/10.1016/j.wneu.2019.04.146
  17. Iacoangeli M, Colasanti R, Esposito D, et al (2017) Supraorbital subfrontal trans-laminar endoscope-assisted approach for tumors of the posterior third ventricle. Acta Neurochirurgica 159:645–654. https://doi.org/10.1007/s00701-017-3117-0 [doi]
  18. Juan Y-H, Hsu M-Y, Yeow K-M, et al (2010) Primary glioblastoma multiforme in the pineal region: A case report with diagnostic imaging findings, treatment response, and literature review. Chinese Journal of Radiology 35:115–123
  19. Kalyanaraman UP (1979) Primary Glioblastoma of the Pineal Gland. Archives of Neurology 36:717–718. https://doi.org/10.1001/archneur.1979.00500470087020
  20. Khalatbari MR, Khalatbari S, Moharamzad Y (2014) Fatal intratumoral hemorrhage in tectal plate glioblastoma multiforme following ventriculoperitoneal shunt. Journal of Pediatric Neurosciences 9:192–195. https://doi.org/10.4103/1817-1745.139366
  21. Li D, Wen R, Gao Y, et al (2020) Pineal Region Gliomas: A Single-Center Experience with 25 Cases. World Neurosurg 133:e6–e17. https://doi.org/10.1016/j.wneu.2019.06.189
  22. Lim JX, Leong A, Tan AP, et al (2020) H3K27M-mutant diffuse midline glioma presenting as synchronous lesions involving pineal and suprasellar region: A case report and literature review. Journal of Clinical Neuroscience 81:144–148. https://doi.org/10.1016/j.jocn.2020.09.029
  23. Liu W, Raynald, Tian Y, et al (2020) Simultaneous single-trajectory endoscopic biopsy and third ventriculostomy in pediatric pineal region tumors. Acta Neurol Belg. https://doi.org/10.1007/s13760-020-01387-2
  24. Liu Y, Hao S, Yu L, Gao Z (2015) Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: A case report and literature review. World Journal of Surgical Oncology 13:. https://doi.org/10.1186/s12957-015-0558-x
  25. Mansour J, Fields B, Macomson S, Rixe O (2014) Significant anti-tumor effect of bevacizumab in treatment of pineal gland glioblastoma multiforme. Target Oncol 9:395–398. https://doi.org/10.1007/s11523-014-0327-8
  26. Matsuda R, Hironaka Y, Suigimoto T, Nakase H (2015) Glioblastoma multiforme in the pineal region with leptomeningeal dissemination and lumbar metastasis. Journal of Korean Neurosurgical Society 58:479–482. https://doi.org/10.3340/jkns.2015.58.5.479
  27. Moon KS, Jung S, Jung TY, et al (2008) Primary glioblastoma in the pineal region: a case report and review of the literature. Journal of medical case reports 2:288-1947-2–288. https://doi.org/10.1186/1752-1947-2-288 [doi]
  28. Nadvi SS, Timatkia K (2018) Primary pineal glioblastoma multiforme mimicking a germ cell tumour. British journal of neurosurgery 32:456–457. https://doi.org/10.1080/02688697.2016.1265084
  29. Nemer MD, Blight C, Yeung JT, et al (2011) Tectal plate glioblastoma multiforme. Surgical neurology international 2:101-7806.83025. Epub 2011 Jul 18. https://doi.org/10.4103/2152-7806.83025 [doi]
  30. Neto FC, Lopes A, Filho MA, et al (2007) Tectal glioblastoma. Arquivos de Neuro-Psiquiatria 65:996–999. https://doi.org/10.1590/s0004-282x2007000600015
  31. Norbut AM, Mendelow H (1981) Primary glioblastoma multiforme of the pineal region with leptomeningeal metastases: a case report. Cancer 47:592–596. https://doi.org/10.1002/1097-0142(19810201)47:3<592::aid-cncr2820470328>3.0.co;2-g
  32. Orrego E, Casavilca S, Garcia-Corrochano P, et al (2017) Glioblastoma of pineal region: report of four cases and literature review. CNS oncology 6:251–259. https://doi.org/10.2217/cns-2016-0047
  33. Ozgural O, Kahilogullari G, Bozkurt M, et al (2013) Primary pineal glioblastoma: A case report. Turkish Neurosurgery 23:572–574. https://doi.org/10.5137/1019-5149.JTN.5994-12.1
  34. Page LK (1977) The infratentorial-supracerebellar exposure of tumors in the pineal area. Neurosurgery 1:36–40. https://doi.org/10.1227/00006123-197707000-00008
  35. Peterson JC, Chamoun RB, Liverman CS (2014) High-failure rate of ETV in pineal region glioblastoma. Neurosurgery Quarterly 24:259–262. https://doi.org/10.1097/wnq.0000000000000141
  36. Pople IK, Arango JC, Scaravilli F (1993) Intrinsic malignant glioma of the pineal gland. Childs Nerv Syst 9:422–424. https://doi.org/10.1007/BF00306198
  37. Sajan A, Hewitt K, Soleiman A, Velayudhan V (2020) Pineal glioblastoma: Case report and literature review of an exceedingly rare etiology for pineal region mass. Clinical imaging 60:95–99. https://doi.org/10.1016/j.clinimag.2019.12.002
  38. Sugita Y, Terasaki M, Tanigawa K, et al (2016) Gliosarcomas arising from the pineal gland region: uncommon localization and rare tumors. Neuropathology : official journal of the Japanese Society of Neuropathology 36:56–63. https://doi.org/10.1111/neup.12226 [doi]
  39. Suzuki R, Suzuki K, Sugiura Y, et al (2014) A case of glioblastoma multiforme in the pineal region with intraventricular hemorrhage. Neurological Surgery 42:429–435
  40. Thaher F, Kurucz P, Fuellbier L, et al (2014) Endoscopic surgery for tumors of the pineal region via a paramedian infratentorial supracerebellar keyhole approach (PISKA). Neurosurgical review 37:677–684. https://doi.org/10.1007/s10143-014-0567-1 [doi]
  41. Toyooka T, Miyazawa T, Fukui S, et al (2005) Central neurogenic hyperventilation in a conscious man with CSF dissemination from a pineal glioblastoma. Journal of Clinical Neuroscience 12:834–837. https://doi.org/10.1016/j.jocn.2004.09.027
  42. Vaquero J, Ramiro J, Martinez R (1990) Glioblastoma multiforme of the pineal region. Journal of neurosurgical sciences 34:149–150
  43. Yerneni K, Fatemi P, Vogel H, et al (2020) Leptomeningeal spread with spinal involvement of pineal glioblastoma at initial presentation: A case report. Interdisciplinary Neurosurgery: Advanced Techniques and Case Management 21:. https://doi.org/10.1016/j.inat.2019.100658
  44. Edwards MS, Hudgins RJ, Wilson CB, et al (1988) Pineal region tumors in children. Journal of neurosurgery 68:689–697. https://doi.org/10.3171/jns.1988.68.5.0689 [doi]
  45. Frank F, Gaist G, Piazza G, et al (1985) Stereotaxic biopsy and radioactive implantation for interstitial therapy of tumors of the pineal region. Surg Neurol 23:275–280. https://doi.org/10.1016/0090-3019(85)90095-3
  46. Granados AM, Ospina C, Paredes S (2018) Pineal gliosarcoma in a 5-year-old girl. Radiol Case Rep 13:244–247. https://doi.org/10.1016/j.radcr.2017.11.003
  47. Miyaji Y, Yagishita S, Zhang N, et al (2014) Obstructive hydrocephalus and leptomeningeal dissemination with an unknown primary lesion in a 67-year-old man. Neuropathology 34:596–601. https://doi.org/10.1111/neup.12136
  48. Oi S, Shibata M, Tominaga J, et al (2000) Efficacy of neuroendoscopic procedures in minimally invasive preferential management of pineal region tumors: a prospective study. J Neurosurg 93:245–253. https://doi.org/10.3171/jns.2000.93.2.0245
  49. Witt O, Schweigerer L, Driever PH, et al (2004) Valproic acid treatment of glioblastoma multiforme in a child. Pediatr Blood Cancer 43:181. https://doi.org/10.1002/pbc.20083
  50. Karremann M, Gielen GH, Hoffmann M, et al (2018) Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location. Neuro Oncol 20:123–131. https://doi.org/10.1093/neuonc/nox149
  51. Louis DN, Perry A, Reifenberger G, et al (2016) The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathologica 131:803–820. https://doi.org/10.1007/s00401-016-1545-1 [doi]
  52. Wang L, Li Z, Zhang M, et al (2018) H3 K27M-mutant diffuse midline gliomas in different anatomical locations. Hum Pathol 78:89–96. https://doi.org/10.1016/j.humpath.2018.04.015
  53. Brown TJ, Brennan MC, Li M, et al (2016) Association of the Extent of Resection With Survival in Glioblastoma: A Systematic Review and Meta-analysis. JAMA Oncol 2:1460–1469. https://doi.org/10.1001/jamaoncol.2016.1373
  54. Esquenazi Y, Friedman E, Liu Z, et al (2017) The Survival Advantage of “Supratotal” Resection of Glioblastoma Using Selective Cortical Mapping and the Subpial Technique. Neurosurgery 81:275–288. https://doi.org/10.1093/neuros/nyw174
  55. Jackson C, Choi J, Khalafallah AM, et al (2020) A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neurooncol 148:419–431. https://doi.org/10.1007/s11060-020-03556-y
  56. Niu X, Wang T, Zhou X, et al (2020) Surgical treatment and survival outcome of patients with adult thalamic glioma: a single institution experience of 8 years. J Neurooncol 147:377–386. https://doi.org/10.1007/s11060-020-03430-x
  57. Choque-Velasquez J, Resendiz-Nieves J, Jahromi BR, et al (2019) Extent of resection and long-term survival of pineal region tumors in Helsinki Neurosurgery. World neurosurgery. https://doi.org/S1878-8750(19)32085-6 [pii]
  58. Choque-Velasquez J, Resendiz-Nieves J, Jahromi BR, et al (2020) Long-term survival outcomes of pineal region gliomas. J Neurooncol 148:651–658. https://doi.org/10.1007/s11060-020-03571-z
  59. Wesseling P, Capper D (2018) WHO 2016 Classification of gliomas. Neuropathology and applied neurobiology 44:139–150. https://doi.org/10.1111/nan.12432 [doi]
  60. Perry A, Wesseling P (2016) Histologic classification of gliomas. Handbook of clinical neurology 134:71–95. https://doi.org/10.1016/B978-0-12-802997-8.00005-0 [doi]

Tables

Table 1. General characteristics of pineal glioblastoma multiforme patients.

 

All*

(N: 70)

Age ≤ 20 years (N:15)

Age > 20 years (N:55)

N

p-value

Sex (male)

41 (60%)

5 (36%)

36 (67%)

68

0.063

Hydrocephalus

52 (87%)

10 (83%)

42 (88%)

60

0.7

Tumor diameter

29 ± 11 (6 – 50) mm

30 ± 12 (20-50) mm

29 ± 11 (6-50) mm

36

0.8

Intracranial dissemination at initial presentation

11 (22%)

1 (9%)

10 (26%)

50

0.4

Spinal dissemination at initial presentation

1 (3%)

0

1 (3%)

40

1

Biopsy

21 (33%)

8 (62%)

13 (26%)

63

0.023

Complete microsurgical resection

12 (19%)

0

12 (24%)

63

0.057

Radiotherapy

53 (88%)

11 (85%)

42 (89%)

60

0.6

Chemotherapy

44 (77%)

9 (75%)

35 (78%)

57

1

Radiotherapy plus chemotherapy

41 (76%)

8 (73%)

33 (77%)

54

1

Last MRI evaluation

 

       

No disease progression

13 (27%)

3 (33%)

10 (25%)

49

0.7

local progression and recurrence

24 (49%)

2 (22%)

22 (55%)

49

0.1

Intracranial dissemination

12 (25%)

4 (44%)

8 (20%)

49

0.2

Spinal dissemination

7 (14%)

2 (22%)

5 (13%)

49

0.6

Postoperative complications

4 (8%)

1 (11%)

3 (8%)

48

1

Follow-up (months)

12 ± 10 (0-42) months

12 ± 11 (0-42) months

12 ± 10 (0-42) months

54

0.8

Mortality

44 (69%)

7 (50%)

37 (74%)

64

0.1

*Age was unreported in 2 patients.

 

Table 2. Pineal glioblastoma multiforme patients distributed by tumor management.

 

All*

(N: 64)

Biopsy

(N:21)

Surgical Removal (N:43)

N

p-value

Age

38±19 (1-74)

35±22 (8-69)

40±18 (1-74)

63

0.2

Sex (male)

38 (61%)

10 (48%)

28 (68%)

62

0.2

Hydrocephalus

47 (86%)

18 (90%)

29 (83%)

55

0.7

Tumor diameter

30±10 (6-50)

24±5 (20-32)

30±11 (6-50)

35

0.2

Intracranial dissemination at initial presentation

10 (21%)

4 (25%)

6 (19%)

47

0.7

Spinal dissemination at initial presentation

1 (3%)

1 (9%)

0

38

0.3

Radiotherapy

49 (88%)

19 (91%)

30 (86%)

56

0.7

Chemotherapy

41 (77%)

13 (77%)

28 (78%)

53

1

Radiotherapy plus chemotherapy

38 (76%)

13 (77%)

25 (76%)

50

1

Last MRI evaluation

 

       

No disease progression

11 (24%)

5 (39%)

6 (18%)

46

0.3

local progression and recurrence

24 (52.2%)

3 (23%)

21 (64%)

46

0.021

Intracranial dissemination

11 (24%)

4 (31%)

7 (21%)

46

0.7

Spinal dissemination

7 (15%)

4 (31%)

3 (9%)

46

0.087

Postoperative complications

4 (9%)

2 (14%)

2 (7%)

45

0.6

Follow-up (months)

12±10 (0-42)

14±13 (0-42)

11±8 (0-32)

63

0.2

Mortality

40 (68%)

9 (45%)

31 (80%)

59

0.017

MOS (95% CI) (months)

12±2 (8-16)

19±2 (15-23)

12±1 (10-14)

59

0.018

 

Table 3. Pineal glioblastoma multiforme patients distributed by radiochemotherapy delivery. MOS, median overall survival; MRI, magnetic resonance imaging.

 

All

(N: 56)

Radiochemotherapy (N: 42)

Surgery alone

(N: 16)

N

p-value

Age

39 ± 19 (5-74)

38 ± 19 (5-74)

41 ± 21 (8-68)

54

0.6

Sex (male)

36 (67%)

29 (71%)

7 (54%)

54

0.3

Hydrocephalus

43 (86%)

32 (84%)

11 (92%)

50

1

Tumor diameter

28 ± 10 (6-50)

27 ± 11 (6-50)

29 ± 9 (20-46)

27

0.6

Intracranial dissemination at initial presentation

10 (23%)

9 (28%)

1 (9%)

43

0.4

Spinal dissemination at initial presentation

1 (3%)

1 (4%)

0

36

1

Biopsy

17 (34%)

13 (34%)

4 (33%)

50

1

Complete microsurgical resection

11 (22%)

10 (26%)

1 (8%)

50

0.3

No disease progression at last MRI

11 (29%)

10 (33%)

1 (13%)

38

0.4

Follow-up (months)

13 ± 10 (0-42)

14 ± 10 (1-42)

9 ± 11 (0-42)

53

0.08

Mortality

36 (68%)

24 (60%)

12 (92%)

53

0.041

MOS (95% CI) (months)

15±4 (8-22)

18±3 (13-23)

6±1 (3-9)

53

0.002

 

 

Table 4. Genetic profile of pineal glioblastoma multiforme patients

Case

Year and author

Age

Sex

Initial regional metastasis

Extent of resection

Radiotherapy

Chemotherapy

PTEN mutation

H3K27M Mutation

Ki-67(%)

IDH1 Mutation

ATRX lost

1p/19q co-deletion

MGMTp methylation

P53

EGFRvIII

Minimum follow-up

Final status

1

2010 Birbilis

57

F

No

B

Yes

Yes

nai

nai

nai

nai

nai

nai

nai

+

nai

40

Death

2

2011 Nemer

45

F

No

PR

No

No

nai

nai

50

nai

nai

nai

nai

+

nai

nai

nai

3

2014 Miyaji

67

M

No

nai

nai

nai

nai

nai

30

-

nai

nai

nai

-

-

9

Death

4

2014 Peterson

20

M

No

B

Yes

Yes

nai

nai

25

nai

nai

nai

nai

+

nai

10

Death

5

2015 Liu

30

M

Yes

PR

Yes

Yes

+

nai

nai

nai

nai

-

+

+

+

15

Alive

6

2015 Matsuda

31

F

No

STR

Yes

Yes

nai

nai

44

nai

nai

nai

nai

nai

nai

5

Death

7

2016 Sugita

18

M

No

PR

Yes

Yes

nai

nai

nai

-

nai

nai

nai

nai

nai

13

Death

8

2016 Sugita

52

F

No

GTR

Yes

Yes

nai

nai

nai

-

nai

nai

nai

nai

nai

24

Death

9

2017 Orrego

25

M

No

GTR

Yes

Yes

nai

nai

30

nai

nai

nai

nai

-

nai

32

Death

10

2017 Orrego

50

M

No

PR

Yes

No

nai

nai

9

nai

nai

nai

nai

nai

nai

6

Death

11

2017 Orrego

56

M

No

PR

Yes

Yes

nai

nai

40

nai

nai

nai

nai

+

nai

29

Death

12

2017 Stowe

65

M

No

B

Yes

Yes

nai

nai

nai

-

nai

nai

+

nai

nai

42

Alive

13

2018 Damico

36

M

No

STR

Yes

No

nai

-

41

-

+

-

-

nai

nai

10

Death

14

2018 Damico

38

M

Yes

PR

Yes

Yes

nai

+

9.3

-

+

nai

nai

nai

nai

23

Death

15

2018 Damico

38

M

No

GTR

Yes

Yes

nai

nai

50

nai

nai

nai

nai

nai

nai

20

Death

16

2018 Damico

46

F

No

GTR

Yes

Yes

nai

-

12

-

+

nai

-

nai

-

15

Death

17

2018 Damico

51

M

No

GTR

Yes

Yes

nai

-

40

-

-

-

-

nai

-

24

Death

18

2018 Damico

52

M

No

GTR

No

No

nai

-

5.2

-

+

nai

nai

nai

-

2

Death

19

2018 Damico

74

M

No

GTR

Yes

Yes

nai

-

13

-

+

-

-

nai

-

8

Death

20

2018 Demir

8

M

Yes

B

Yes

Yes

nai

+

nai

nai

nai

nai

nai

nai

nai

3

Alive

21

2018 Gilbert

12

F

No

STR

nai

Yes

nai

+

nai

nai

nai

nai

nai

nai

nai

8

Alive

22

2018 Granados

5

F

nai

nai

Yes

Yes

nai

nai

90

nai

nai

nai

nai

nai

nai

3

Alive

23

2020 Lim

22

F

Yes

B

Yes

Yes

nai

+

nai

-

-

nai

-

+

nai

7

Alive

24

2020 Niu

21

M

Yes

STR

Yes

Yes

nai

+

8

-

+

nai

-

+

-

16

Alive

25

2020 Niu

30

M

Yes

STR

Yes

Yes

nai

+

20

-

-

nai

nai

+

nai

12

Death

26

2020 Niu

55

M

Yes

STR

No

No

nai

-

20

-

-

nai

-

+

nai

10

Death

27

2020 Sajan

39

F

No

B

Yes

Yes

nai

+

nai

+

nai

+

+

nai

+

12

Alive

28

2020 Yerneni

51

M

Yes

B

Yes

Yes

+

nai

nai

nai

nai

nai

nai

+

nai

2

Alive

29

2021 Dono

24

M

Nai

B

Yes

Yes

nai

-

nai

nai

nai

nai

nai

nai

nai

19

Death

30

2021 Dono

54

M

Nai

STR

Yes

Yes

nai

-

nai

nai

nai

nai

nai

nai

nai

12.1

Alive

 

Table 5. Predictors after univariate and multivariate survival Cox model of pineal region glioblastoma multiforme. HR, hazard ratio; CI, confidence interval; CMT, chemotherapy; RT, radiotherapy; GTR, gross total resection. Values with statistical significance in bold.

Overall survival

 

Univariate model

Multivariate model

Variable

 HR

95.0% CI for HR

p-value

HR

95.0% CI for HR

p-value

Sex

0.850

0.455 , 1.589

0.611

 

 

 

Hydrocephalus

0.110

0.115 , 1.247

0.110

 

 

 

Biopsy

2.463

1.118 , 5.427

0.025

4.155

1.496 , 10.291

0.005

CMT

2.625

1.308 , 5.268

0.007

 

 

 

RT

4.103

1.670 , 10.083

0.002

 

 

 

RT + CMT

2.802

1.381 , 5.685

0.004

4.118

1.774 , 9.558

<0.001

GTR

0.877

0.412 , 1.868

0.735

 

 

 

Regional metastasis

0.930

0.375 , 2.303

0.875

 

 

 

Maximal tumor dimension

0.997

0.960 , 1.037

0.897